E Jantunen


Affiliation: Kuopio University Hospital
Country: Finland


  1. Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol. 2010;85:463-71 pubmed publisher
    ..This review attempts to summarize current treatment strategies in hard-to-mobilize patients with lymphoid malignancies. ..
  2. Jantunen E, Kuittinen T, Mahlamaki E, Pyörälä M, Mäntymaa P, Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol. 2011;86:299-304 pubmed publisher
    ..In patients with low but rising B-CD34(+) counts, the use of plerixafor might be delayed as late mobilization may occur. Further studies are needed to optimize patient selection and timing of plerixafor. ..
  3. Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant. 2011;46:627-35 pubmed publisher
    ..These studies are not only important in regard to defining the optimal stem-cell graft in the autologous setting, but also in identifying the optimal mobilization regimen. ..
  4. Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther. 2011;11:1241-8 pubmed publisher
    ..Novel mobilization strategies have allowed more successful stem cell collection in autologous setting, although the effect of plerixafor on graft content and long-term patient outcomes needs further investigation. ..
  5. Jantunen E, Lemoli R. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion. 2012;52:906-14 pubmed publisher
  6. Jantunen E, Varmavuo V, Juutilainen A, Kuittinen T, Mahlamaki E, Mäntymaa P, et al. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol. 2012;91:1073-9 pubmed publisher
    ..97 and specificity 1.00, respectively, to identify patients for plerixafor use provided that all patients with B-CD34+ maximum ?10×10(6)/l would have needed plerixafor.This simple model needs a prospective validation. ..
  7. Jantunen E, Kuittinen T. Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. Eur J Haematol. 2008;80:287-95 pubmed publisher
    ..There seems to be even more disease-specific issues in blood stem cell mobilization in patients with chronic lymphocytic leukaemia and in patients with light chain amyloidosis. We also discuss options in hard-to-mobilize patients. ..
  8. request reprint
    Jantunen E, Itala M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant. 2008;41:239-44 pubmed
    ..001). A significant proportion of patients with CLL were difficult to mobilize. Adequate marrow function including platelet counts >100 x 10(9)/l seem to be important factors in terms of successful blood stem cell collection. ..